Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America
- Ignacio F. Mata,
- Greggory J. Wilhoite,
- Dora Yearout,
- Justin A. Bacon,
- ,
- Pilar Mazzetti
- VA Puget Sound Health Care System,
- University of Washington School of Medicine,
- Mayo Clinic in Jacksonville, Florida,
- docencia y atención especializada en epilepsia,
- Universidad Nacional Mayor de San Marcos,
- Universidad Nacional del Altiplano
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 629-631 (3 pages)Journal (Volume, Issue Number)
Parkinsonism and Related Disorders (Volume 17, Issue 8)Publication milestones
- Published - 09/2011
Publication status
ISSN
1353-8020Publication IDs
- Scopus: 80052366563
- PubMed: 21632271
Abstract
Mutations in the LRRK2 gene are the most common genetic cause of Parkinson's disease, with frequencies displaying a high degree of population-specificity. Although more than 100 coding substitutions have been identified, only seven have been proven to be highly penetrant pathogenic mutations. Studies however are lacking in non-white populations. Recently, Lrrk2 p.Q1111H (rs78365431) was identified in two affected Hispanic brothers and absent in 386 non-Hispanic white healthy controls. We therefore screened this variant in 1460 individuals (1150 PD patients and 310 healthy controls) from 4 Latin American countries (Peru, Chile, Uruguay and Argentina).In our case-control series from Peru and Chile we observed an increased frequency of Lrrk2 p.Q1111H in patients (7.9%) compared to controls (5.4%) although the difference did not reach significance (OR 1.38; p = 0.10).In addition, the frequency of Lrrk2 p.Q1111H varied greatly between populations and further screening in a set of pure Amerindian and pure Spanish controls suggested that this variant likely originated in an Amerindian population. Further studies in other Latin American populations are warranted to assess its role as a risk factor for Parkinson's disease. Screening in Parkinson's disease patients from under-represented populations will increase our understanding of the role of LRRK2 variants in disease risk worldwide.
